• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    2/13/24 4:30:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care
    Get the next $LNSR alert in real time by email
    SC 13G/A 1 curtis-2024-13ga.htm SC 13G/A SC 13G/A

     

    ______________________________________________________________________________

     

    United States

    Securities and Exchange Commission

    Washington, D.C. 20549

    Schedule 13G

    (Rule 13d-102)
     

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (Amendment No. 2)*

     

    LENSAR, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.01

    (Title of Class of Securities)

    52634L108

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    ______________________________________________________________________________

     

     


    CUSIP No. 52634L108

    Schedule 13G

    Page 2 of 5

     

         1

    Names of Reporting Persons

    Nicholas T. Curtis

         2

    Check the Appropriate Box if a Member of a Group

    (a) ☐ (b) ☐

         3

    SEC Use Only

         4

    Citizenship or Place of Organization

    United States

    Number of Shares Beneficially Owned by Each Reporting Person With

    5

    Sole Voting Power

    906,808

    6

    Shared Voting Power
    0

    7

    Sole Dispositive Power

    906,808

    8

    Shared Dispositive Power

    0

         9

    Aggregate Amount Beneficially Owned by Each Reporting Person
    906,808

         10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
    Not Applicable

         11

    Percent of Class Represented by Amount in Row 9
    7.9%

         12

    Type of Reporting Person
    IN

     

     


    CUSIP No. 52634L108

    Schedule 13G

    Page 3 of 5

     

    ITEM 1.
    (a) Name of Issuer:

    LENSAR, Inc. (the “Issuer”).

    (a)
    Address of Issuer’s Principal Executive Offices:

     

    2800 Discovery Drive, Orlando, FL 32826.

    ITEM 2.
    (a) Name of Person Filing:

    This statement is filed on behalf of Nicholas T. Curtis (the “Reporting Person”).

    (a)
    Address of Principal Business Office:

    The business address of the Reporting Person is c/o LENSAR, Inc., 2800 Discovery Drive, Orlando, FL 32826.

    (b)
    Citizenship:

     

    The Reporting Person is a citizen of the United States.

    (c)
    Title of Class of Securities:

     

    Common stock, par value $0.01 per share (“Common Stock”).

    (d)
    CUSIP Number:

     

    52634L108

    ITEM 3.

    Not applicable.

    ITEM 4.
    Ownership.

     

    The ownership information below represents beneficial ownership of shares of Common Stock of the Issuer as of December 31, 2023, based upon 11,248,507 shares of Common Stock outstanding as of October 31, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

    (a) Amount beneficially owned:

    The Reporting Person is the beneficial owner of 906,808 shares of Common Stock, which consists of (i) 748,350 shares of Common Stock held of record by the Reporting Person, (ii) 145,412 shares of Common Stock underlying stock options that are exercisable on or prior to February 29, 2024 and (iii) 13,046 shares of

     

     


    CUSIP No. 52634L108

    Schedule 13G

    Page 4 of 5

     

    Common Stock underlying restricted stock units that will vest on or prior to February 29, 2024.

    (b) Percent of class: 7.9%

    (c) Number of shares as to which the person has:

    (i)
    Sole power to vote or to direct the vote: 906,808
    (ii)
    Shared power to vote or direct the vote: 0
    (iii)
    Sole power to dispose or to direct the disposition of: 906,808
    (iv)
    Shared power to dispose or to direct the disposition of: 0
    ITEM 5.
    Ownership of Five Percent or Less of a Class.

    Not applicable.

    ITEM 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    ITEM 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    ITEM 8.
    Identification and Classification of Members of the Group.

     

    Not applicable.

    ITEM 9.
    Notice of Dissolution of Group.

    Not applicable.

    ITEM 10.
    Certification.

    Not applicable.

     

     

     

     


    CUSIP No. 52634L108

    Schedule 13G

    Page 5 of 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 13, 2024

     

    Nicholas T. Curtis

     

    /s/ Nicholas T. Curtis

     

     

     

     


    Get the next $LNSR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LNSR

    DatePrice TargetRatingAnalyst
    11/22/2021$15.00Buy
    BTIG
    More analyst ratings

    $LNSR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LENSAR Reports First Quarter 2025 Results and Provides Business Update

               14 ALLY Robotic Laser Cataract Systems™ ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2025 and provided an update on key operational initiatives. "W

      5/8/25 7:00:42 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Alcon Agrees to Acquire LENSAR, Inc.

      Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon's cataract equipment and technology portfolioNext generation technology will be expanded globally, improving the efficiency of cataract surgery GENEVA and ORLANDO, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ:LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR. The acquisition includes ALLY Robotic Cataract Laser Treatment Sy

      3/24/25 8:00:00 AM ET
      $ALC
      $LNSR
      Ophthalmic Goods
      Health Care
      Medical/Dental Instruments
    • LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 1,600 shares of the Company's common stock. The options were granted as of March 3, 2025, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $13.48 per share, which is equal to the closing price of the Company's common stock on the grant date. The options vest as t

      3/3/25 7:03:12 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ellis Thomas B was granted 7,374 shares, increasing direct ownership by 24% to 38,662 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      5/28/25 4:57:30 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Director Hammer Todd B was granted 7,374 shares, increasing direct ownership by 24% to 38,662 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      5/28/25 4:56:24 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Director Winer Gary M was granted 7,374 shares, increasing direct ownership by 9% to 88,214 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      5/28/25 4:30:14 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Winer Gary M bought $3,082 worth of shares (685 units at $4.50), increasing direct ownership by 0.85% to 80,840 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      9/6/24 9:00:13 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Director Winer Gary M bought $10,373 worth of shares (2,302 units at $4.51), increasing direct ownership by 3% to 80,155 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      8/29/24 6:05:46 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Director Winer Gary M bought $2,185 worth of shares (502 units at $4.35), increasing direct ownership by 0.65% to 77,853 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      8/23/24 6:52:16 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    SEC Filings

    See more
    • SEC Form DEFA14A filed by LENSAR Inc.

      DEFA14A - LENSAR, Inc. (0001320350) (Filer)

      5/22/25 4:47:59 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by LENSAR Inc.

      8-K - LENSAR, Inc. (0001320350) (Filer)

      5/22/25 4:43:59 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFM14A filed by LENSAR Inc.

      DEFM14A - LENSAR, Inc. (0001320350) (Filer)

      5/19/25 4:31:39 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG initiated coverage on LENSAR with a new price target

      BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00

      11/22/21 6:09:40 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SVB Leerink initiated coverage on LENSAR with a new price target

      SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

      3/2/21 8:10:50 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SVB Leerink initiated coverage on LENSAR with a new price target

      SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

      2/24/21 6:12:20 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Financials

    Live finance-specific insights

    See more
    • LENSAR Reports First Quarter 2025 Results and Provides Business Update

               14 ALLY Robotic Laser Cataract Systems™ ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2025 and provided an update on key operational initiatives. "W

      5/8/25 7:00:42 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

      31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financia

      2/27/25 7:00:11 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • LENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025

      ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2024 financial results will be released before market open on Thursday, February 27, 2025. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, February 27, 2025 to discuss the financial results and recent corporate highlights. To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance

      2/19/25 12:00:25 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by LENSAR Inc.

      SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

      11/14/24 4:05:15 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

      SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

      2/14/24 4:05:39 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

      SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

      2/13/24 4:30:02 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care